僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類或動物的臨床診斷或治療，非藥用.Dasatinib （BMS-354825） is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib also induces apoptosis and autophagy.